Immunopharmacology of rapamycin
- PMID: 8717522
- DOI: 10.1146/annurev.immunol.14.1.483
Immunopharmacology of rapamycin
Abstract
The potent immunosuppressive drugs FK506 and rapamycin interfere with signal transduction pathways required for T cell activation and growth. The distinct inhibitory effects of these drugs on the T cell activation program are mediated through the formation of pharmacologically active complexes with members of a family of intracellular receptors termed the FK506 binding proteins (FKBPs). The FKBP12.FK506 complex specifically binds to and inhibits calcineurin, a signaling protein required for transcriptional activation of the interleukin (IL)-2 gene in response to T cell antigen receptor engagement. The FKBP12. rapamycin complex interacts with a recently defined target protein termed the mammalian target of rapamycin (mTOR). Accumulating data suggest that mTOR functions in a previously unrecognized signal transduction pathway required for the progression of IL-2-stimulated T cells from G1 into the S phase of the cell cycle. Here we review the immunopharmacology of rapamycin, with particular emphasis on the characterization of mTOR.
Similar articles
-
FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.Eur J Immunol. 1995 Feb;25(2):563-71. doi: 10.1002/eji.1830250239. Eur J Immunol. 1995. PMID: 7533090
-
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.Oncogene. 2000 Dec 27;19(56):6680-6. doi: 10.1038/sj.onc.1204091. Oncogene. 2000. PMID: 11426655 Review.
-
A mammalian protein targeted by G1-arresting rapamycin-receptor complex.Nature. 1994 Jun 30;369(6483):756-8. doi: 10.1038/369756a0. Nature. 1994. PMID: 8008069
-
Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.Annu Rev Immunol. 1992;10:519-60. doi: 10.1146/annurev.iy.10.040192.002511. Annu Rev Immunol. 1992. PMID: 1375473 Review.
-
Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.Eur J Immunol. 1990 Oct;20(10):2277-83. doi: 10.1002/eji.1830201017. Eur J Immunol. 1990. PMID: 1700753
Cited by
-
Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment.Cancers (Basel). 2021 Mar 17;13(6):1359. doi: 10.3390/cancers13061359. Cancers (Basel). 2021. PMID: 33802831 Free PMC article. Review.
-
Disrupting Reconsolidation by Systemic Inhibition of mTOR Kinase via Rapamycin Reduces Cocaine-Seeking Behavior.Front Pharmacol. 2021 Apr 9;12:652865. doi: 10.3389/fphar.2021.652865. eCollection 2021. Front Pharmacol. 2021. PMID: 33897438 Free PMC article.
-
Chemical Biology Strategies to Study Autophagy.Front Cell Dev Biol. 2018 Nov 27;6:160. doi: 10.3389/fcell.2018.00160. eCollection 2018. Front Cell Dev Biol. 2018. PMID: 30538986 Free PMC article. Review.
-
A novel myelin protein zero transgenic zebrafish designed for rapid readout of in vivo myelination.Glia. 2019 Apr;67(4):650-667. doi: 10.1002/glia.23559. Epub 2019 Jan 9. Glia. 2019. PMID: 30623975 Free PMC article.
-
Effects of mTORC1 inhibition on proteasome activity and levels.BMB Rep. 2022 Apr;55(4):161-165. doi: 10.5483/BMBRep.2022.55.4.032. BMB Rep. 2022. PMID: 35321785 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous